AU2015204531B2 - Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same - Google Patents

Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same Download PDF

Info

Publication number
AU2015204531B2
AU2015204531B2 AU2015204531A AU2015204531A AU2015204531B2 AU 2015204531 B2 AU2015204531 B2 AU 2015204531B2 AU 2015204531 A AU2015204531 A AU 2015204531A AU 2015204531 A AU2015204531 A AU 2015204531A AU 2015204531 B2 AU2015204531 B2 AU 2015204531B2
Authority
AU
Australia
Prior art keywords
day
per day
hepe
per
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015204531A
Other languages
English (en)
Other versions
AU2015204531A1 (en
Inventor
John Climax
Kevin Duffy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afimmune Ltd
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of AU2015204531A1 publication Critical patent/AU2015204531A1/en
Assigned to DIGNITY SCIENCES LIMITED reassignment DIGNITY SCIENCES LIMITED Request for Assignment Assignors: CLIMAX, JOHN, DUFFY, KEVIN, MANKU, MEHAR
Assigned to AFIMMUNE LIMITED reassignment AFIMMUNE LIMITED Request for Assignment Assignors: DIGNITY SCIENCES LIMITED
Application granted granted Critical
Publication of AU2015204531B2 publication Critical patent/AU2015204531B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2015204531A 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same Ceased AU2015204531B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461926052P 2014-01-10 2014-01-10
US61/926,052 2014-01-10
PCT/US2015/011054 WO2015106215A2 (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Publications (2)

Publication Number Publication Date
AU2015204531A1 AU2015204531A1 (en) 2016-08-18
AU2015204531B2 true AU2015204531B2 (en) 2019-11-14

Family

ID=53520398

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015204531A Ceased AU2015204531B2 (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same

Country Status (15)

Country Link
US (2) US20150196521A1 (enrdf_load_stackoverflow)
EP (1) EP3091959A4 (enrdf_load_stackoverflow)
JP (2) JP2017505809A (enrdf_load_stackoverflow)
KR (1) KR20160132372A (enrdf_load_stackoverflow)
CN (1) CN106029051A (enrdf_load_stackoverflow)
AU (1) AU2015204531B2 (enrdf_load_stackoverflow)
BR (1) BR112016015997A2 (enrdf_load_stackoverflow)
CA (1) CA2935986A1 (enrdf_load_stackoverflow)
IL (1) IL246623A0 (enrdf_load_stackoverflow)
MX (1) MX2016008953A (enrdf_load_stackoverflow)
PH (1) PH12016501371A1 (enrdf_load_stackoverflow)
RU (2) RU2685706C2 (enrdf_load_stackoverflow)
SG (2) SG10202000496XA (enrdf_load_stackoverflow)
WO (1) WO2015106215A2 (enrdf_load_stackoverflow)
ZA (1) ZA201605492B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170006A2 (en) 2012-05-10 2013-11-14 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
CN107405324A (zh) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 包含15‑hepe的组合物和其使用方法
WO2017013492A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055538A1 (en) * 2000-02-16 2002-05-09 Serhan Charles N. Aspirin-triggered lipid mediators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20060160095A1 (en) * 2002-12-13 2006-07-20 Eirx Therapeutics Limited Survivin
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013170006A2 (en) * 2012-05-10 2013-11-14 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055538A1 (en) * 2000-02-16 2002-05-09 Serhan Charles N. Aspirin-triggered lipid mediators

Also Published As

Publication number Publication date
CN106029051A (zh) 2016-10-12
SG10202000496XA (en) 2020-03-30
US20150196521A1 (en) 2015-07-16
WO2015106215A2 (en) 2015-07-16
RU2016132762A3 (enrdf_load_stackoverflow) 2018-09-20
ZA201605492B (en) 2018-11-28
AU2015204531A1 (en) 2016-08-18
RU2016132762A (ru) 2018-02-16
MX2016008953A (es) 2017-02-02
RU2019110980A (ru) 2019-08-26
RU2685706C2 (ru) 2019-04-23
BR112016015997A2 (pt) 2018-03-27
IL246623A0 (en) 2016-08-31
WO2015106215A3 (en) 2016-02-18
CA2935986A1 (en) 2015-07-16
KR20160132372A (ko) 2016-11-18
SG11201605601UA (en) 2016-08-30
JP2017505809A (ja) 2017-02-23
US20160324820A1 (en) 2016-11-10
EP3091959A2 (en) 2016-11-16
JP2020002150A (ja) 2020-01-09
EP3091959A4 (en) 2017-09-20
PH12016501371A1 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
AU2015204531B2 (en) Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
KR100234864B1 (ko) 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
JP2004507494A (ja) サルメテロールとプロピオン酸フルチカゾンとの合剤の使用
Westbroek et al. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma
JP2021505630A (ja) 慢性閉塞性肺疾患の急性増悪の予防または減少における３−［５−アミノ−４−（３−シアノベンゾイル）−ピラゾール−１−イル］−ｎ−シクロプロピル−４−メチルベンズアミドの使用
Boldy et al. Nedocromil sodium and sodium cromoglycate in patients aged over 50 years with asthma
Terzano et al. Comparison of the efficacy of beclometasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma
US8809306B2 (en) Combination andolast/glucocorticoids
JP2021505631A (ja) 慢性閉塞性肺疾患の急性増悪の処置における３−［５−アミノ−４−（３−シアノベンゾイル）−ピラゾール−１−イル］−ｎ−シクロプロピル−４−メチルベンズアミドの使用
AU2010322066A1 (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
EP1658063B1 (en) Advantageous combinations for inhalation of nacystelyn and bronchodilators
US20150265621A1 (en) Treating Bronchiectasis With Doxofylline and Erdosteine
Paggiaro et al. Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge
Hawkins How I treat feline bronchitis.
Jassim Comparative clinical study between high doses of beclomethasone inhaler alone and combination of moderate doses of beclomethasone inhaler with either aminophylline or montelukast tablets in persistent asthmatic Iraqi patients
HK1135331B (en) Use of mometasone furoate for treating airway passage and lung diseases
JP2013056925A (ja) アンドラスト／グルココルチコイドの併用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DIGNITY SCIENCES LIMITED

Free format text: FORMER APPLICANT(S): DUFFY, KEVIN; MANKU, MEHAR; CLIMAX, JOHN

PC1 Assignment before grant (sect. 113)

Owner name: AFIMMUNE LIMITED

Free format text: FORMER APPLICANT(S): DIGNITY SCIENCES LIMITED

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTORS TO READ CLIMAX, JOHN AND DUFFY, KEVIN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CLIMAX, JOHN AND DUFFY, KEVIN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired